Levosulpiride

Levosulpiride
Clinical data
Trade names	Dislep, Sulpepta, others
Other names	L-Sulpiride; S-(–)-Sulpiride; RV-12309
Routes of; administration	Oral
ATC code	N05AL07 (WHO) ;
Identifiers
	IUPAC name N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide;
CAS Number	23672-07-3;
PubChem CID	688272;
IUPHAR/BPS	958;
DrugBank	DB16021;
ChemSpider	599749;
UNII	JTG7R315LK;
KEGG	D07312;
ChEBI	CHEBI:64119;
ChEMBL	ChEMBL267044;
CompTox Dashboard (EPA)	DTXSID0042583;
Chemical and physical data
Formula	C15H23N3O4S
Molar mass	341.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC;
	InChI InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1; Key:BGRJTUBHPOOWDU-NSHDSACASA-N;
	(verify)

Levosulpiride, sold under the brand names Dislep and Sulpepta among others, is a dopamine antagonist medication which is used in the treatment of psychotic disorders like schizophrenia, major depressive disorder, nausea and vomiting, and gastroparesis.^[1]^[2]^[3]^[4] It is taken by mouth.

It is a selective antagonist of the dopamine D₂ receptor and an agonist of the serotonin 5-HT₄ receptor.^[4]^[5] Chemically, it is a benzamide and the (S)-(−)-enantiomer of sulpiride.^[4]

Levosulpiride is marketed widely throughout the world, including in Europe, South Korea, Latin America, India, and Pakistan.^[2] It is not available in the United States or the United Kingdom.^[2]

^ "Levosulpiride". AdisInsight. 24 October 2021. Retrieved 22 October 2024.
^ ^a ^b ^c "Levosulpiride (International database)". Drugs.com. 6 October 2024. Retrieved 22 October 2024.
^ Mucci A, Nolfe G, Maj M (February 1995). "Levosulpiride: a review of its clinical use in psychiatry". Pharmacol Res. 31 (2): 95–101. doi:10.1016/1043-6618(95)80053-0. PMID 7596960.
^ ^a ^b ^c Rossi F, Forgione A (February 1995). "Pharmacotoxicological aspects of levosulpiride". Pharmacol Res. 31 (2): 81–94. doi:10.1016/1043-6618(95)80052-2. PMID 7596959.
^ Tonini M, De Giorgio R, Spelta V, Bassotti G, Di Nucci A, Anselmi L, Balestra B, De Ponti F (April 2003). "5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract". Dig Liver Dis. 35 (4): 244–250. doi:10.1016/s1590-8658(03)00061-6. PMID 12801035.

[AdisInsight-1] "Levosulpiride". AdisInsight. 24 October 2021. Retrieved 22 October 2024.

[Drugs.com-International-2] "Levosulpiride (International database)". Drugs.com. 6 October 2024. Retrieved 22 October 2024.

[MucciNolfeMaj1995-3] Mucci A, Nolfe G, Maj M (February 1995). "Levosulpiride: a review of its clinical use in psychiatry". Pharmacol Res. 31 (2): 95–101. doi:10.1016/1043-6618(95)80053-0. PMID 7596960.

[RossiForgione1995-4] Rossi F, Forgione A (February 1995). "Pharmacotoxicological aspects of levosulpiride". Pharmacol Res. 31 (2): 81–94. doi:10.1016/1043-6618(95)80052-2. PMID 7596959.

[ToniniDeGiorgioSpelta2003-5] Tonini M, De Giorgio R, Spelta V, Bassotti G, Di Nucci A, Anselmi L, Balestra B, De Ponti F (April 2003). "5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract". Dig Liver Dis. 35 (4): 244–250. doi:10.1016/s1590-8658(03)00061-6. PMID 12801035.

[1]

[2]

[3]

[4]

[5]